ABL1 and acute lymphoblastic leukemia: Owing to the dearth of clinically relevant TKI-resistance mutations detectable at diagnosis even with the highest sensitivity sequencing method available, our findings do not support the routine use of pretreatment ABL1 mutation analysis to personalize TKI selection in patients with newly diagnosed Ph + ALL.